These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 31514528)

  • 1. Genetic Ablation of TASK-1 (Tandem of P Domains in a Weak Inward Rectifying K
    Schmidt C; Wiedmann F; Beyersdorf C; Zhao Z; El-Battrawy I; Lan H; Szabo G; Li X; Lang S; Korkmaz-Icöz S; Rapti K; Jungmann A; Ratte A; Müller OJ; Karck M; Seemann G; Akin I; Borggrefe M; Zhou XB; Katus HA; Thomas D
    Circ Arrhythm Electrophysiol; 2019 Sep; 12(9):e007465. PubMed ID: 31514528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cloning, functional characterization, and remodeling of K2P3.1 (TASK-1) potassium channels in a porcine model of atrial fibrillation and heart failure.
    Schmidt C; Wiedmann F; Langer C; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Heart Rhythm; 2014 Oct; 11(10):1798-805. PubMed ID: 24952150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy.
    Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Paasche A; Jávorszky N; Rinné S; Sutanto H; Büscher A; Foerster KI; Blank A; El-Battrawy I; Li X; Lang S; Tochtermann U; Kremer J; Arif R; Karck M; Decher N; van Loon G; Akin I; Borggrefe M; Kallenberger S; Heijman J; Haefeli WE; Katus HA; Schmidt C
    Cardiovasc Res; 2022 Jun; 118(7):1728-1741. PubMed ID: 34028533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of K(2P)3.1 K+ Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation.
    Schmidt C; Wiedmann F; Voigt N; Zhou XB; Heijman J; Lang S; Albert V; Kallenberger S; Ruhparwar A; Szabó G; Kallenbach K; Karck M; Borggrefe M; Biliczki P; Ehrlich JR; Baczkó I; Lugenbiel P; Schweizer PA; Donner BC; Katus HA; Dobrev D; Thomas D
    Circulation; 2015 Jul; 132(2):82-92. PubMed ID: 25951834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
    Schmidt C; Wiedmann F; Zhou XB; Heijman J; Voigt N; Ratte A; Lang S; Kallenberger SM; Campana C; Weymann A; De Simone R; Szabo G; Ruhparwar A; Kallenbach K; Karck M; Ehrlich JR; Baczkó I; Borggrefe M; Ravens U; Dobrev D; Katus HA; Thomas D
    Eur Heart J; 2017 Jun; 38(22):1764-1774. PubMed ID: 28057773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial fibrillation and heart failure-associated remodeling of two-pore-domain potassium (K
    Wiedmann F; Schulte JS; Gomes B; Zafeiriou MP; Ratte A; Rathjens F; Fehrmann E; Scholz B; Voigt N; Müller FU; Thomas D; Katus HA; Schmidt C
    Basic Res Cardiol; 2018 Jun; 113(4):27. PubMed ID: 29881975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. pH-dependent inhibition of K₂P3.1 prolongs atrial refractoriness in whole hearts.
    Skarsfeldt MA; Jepps TA; Bomholtz SH; Abildgaard L; Sørensen US; Gregers E; Svendsen JH; Diness JG; Grunnet M; Schmitt N; Olesen SP; Bentzen BH
    Pflugers Arch; 2016 Apr; 468(4):643-54. PubMed ID: 26729267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac K
    Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis.
    Liang B; Soka M; Christensen AH; Olesen MS; Larsen AP; Knop FK; Wang F; Nielsen JB; Andersen MN; Humphreys D; Mann SA; Huttner IG; Vandenberg JI; Svendsen JH; Haunsø S; Preiss T; Seebohm G; Olesen SP; Schmitt N; Fatkin D
    J Mol Cell Cardiol; 2014 Feb; 67():69-76. PubMed ID: 24374141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac expression and atrial fibrillation-associated remodeling of K₂p2.1 (TREK-1) K⁺ channels in a porcine model.
    Schmidt C; Wiedmann F; Tristram F; Anand P; Wenzel W; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
    Life Sci; 2014 Mar; 97(2):107-15. PubMed ID: 24345461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TREK-1 (K
    Lugenbiel P; Wenz F; Syren P; Geschwill P; Govorov K; Seyler C; Frank D; Schweizer PA; Franke J; Weis T; Bruehl C; Schmack B; Ruhparwar A; Karck M; Frey N; Katus HA; Thomas D
    Basic Res Cardiol; 2017 Jan; 112(1):8. PubMed ID: 28005193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TASK-1 current is inhibited by phosphorylation during human and canine chronic atrial fibrillation.
    Harleton E; Besana A; Chandra P; Danilo P; Rosen TS; Rosen MR; Argenziano M; Robinson RB; Feinmark SJ
    Am J Physiol Heart Circ Physiol; 2015 Jan; 308(2):H126-34. PubMed ID: 25437921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Ca
    Heijman J; Zhou X; Morotti S; Molina CE; Abu-Taha IH; Tekook M; Jespersen T; Zhang Y; Dobrev S; Milting H; Gummert J; Karck M; Kamler M; El-Armouche A; Saljic A; Grandi E; Nattel S; Dobrev D
    Circ Res; 2023 Apr; 132(9):e116-e133. PubMed ID: 36927079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes.
    Lugenbiel P; Govorov K; Syren P; Rahm AK; Wieder T; Wunsch M; Weiberg N; Manolova E; Gramlich D; Rivinius R; Finke D; Lehmann LH; Schweizer PA; Frank D; El Tahry FA; Bruehl C; Heimberger T; Sandke S; Weis T; Most P; Schmack B; Ruhparwar A; Karck M; Frey N; Katus HA; Thomas D
    Basic Res Cardiol; 2021 Feb; 116(1):13. PubMed ID: 33630168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
    Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
    J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TASK-1 and TASK-3 may form heterodimers in human atrial cardiomyocytes.
    Rinné S; Kiper AK; Schlichthörl G; Dittmann S; Netter MF; Limberg SH; Silbernagel N; Zuzarte M; Moosdorf R; Wulf H; Schulze-Bahr E; Rolfes C; Decher N
    J Mol Cell Cardiol; 2015 Apr; 81():71-80. PubMed ID: 25655935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials.
    Dobrev D; Graf E; Wettwer E; Himmel HM; Hála O; Doerfel C; Christ T; Schüler S; Ravens U
    Circulation; 2001 Nov; 104(21):2551-7. PubMed ID: 11714649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation.
    Balana B; Dobrev D; Wettwer E; Christ T; Knaut M; Ravens U
    J Mol Cell Cardiol; 2003 Dec; 35(12):1399-405. PubMed ID: 14654366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inward Rectifier K
    Pluteanu F; Seidl MD; Hamer S; Scholz B; Müller FU
    J Am Heart Assoc; 2020 Dec; 9(23):e016144. PubMed ID: 33191843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.